Program

The 6th edition of the International HBV Cure Workshop featured the world's most prominent and distinguished speakers that discussed the most current and trending issues in the field. 

 

 Wednesday, 6 November 2019

 8:00

Welcome
Harry Janssen
Toronto Centre for Liver Disease, Canada

 Session 1: Review of Nucleoside analogue Stopping studies
Chairs: Marion Peters & David Wong
 8:10

Stopping Nucleos(t)ide Analogues: Clinical outcomes of HBs Loss, retreatment and flares
Pietro Lampertico
University of Milan

 8:25

Virological biomarkers in patients stopping Nucs
Florian van Bommel
University Hospital Leipzig

 8:40

Immunological response after stopping Nucs
Andre Boonstra
Erasmus Medical Center, the Netherlands

 8:55Discussion
   
 Session 2: New Endpoints and Biomarkers
Chairs: Robert Gish & Scott Fung
 9:20 AM

Review of the FDA/EMA HBV Endpoints Meeting
Fabien Zoulim
INSERM, France

 9:35 AM

Are HBcrAg, HBV RNA and anti-HBc Viable Biomarkers
Florian van Bommel
University Hospital Leipzig

 9:50 AM

Are ALT Flares Associated with Improved Virological Clearance
Harry Janssen
Toronto Centre for Liver Disease

 10:05 AMDiscussion
   
 10:25 AMCOFFEE BREAK
   
 Session 3: How to make immunology curative
Chairs: Adam gehring & Georg Lauer
 10:40 PM

High Resolution of Exhausted T cells Ex Vivo in Chronic HBV Infection
Robert Thimme
University of Freiburg, Germany

 10:55 PM

Restoration of B cell Antibody Production in Chronic HBV patients
Mala Maini
University College London

 11:10 PM

Using FNAB to Investigate Intrahepatic Immunology
Adam Gehring
Toronto Centre for Liver Disease, Canada

 11:25 AM

Springbank RIG-I Agonist (Inarigivir)
Cheleas MacFarlane
Springbank Pharmaceuticals, Inc. 

 11:35 AMGilead TLR8 agonist (GS-9688)
Simon Fletcher
Gilead Sciences
 11:45 AM

Roche TLR-7 agonist
Lu Gao
Roche, China

 11:55 AMDiscussion
   
 12:30 PMLunch
   
 Session 4: Update on Viral Targets for HBV/HDV Therapy 
Chairs: Stephen Locarnini & Raymond Schinazi
 1:30 PM

Mechanisms of cccDNA Maintenance and progress on Measurement
Massimo Levrero
Cancer Research Center of Lyon - Inserm U1052

 1:45 PM

Capsid inhibitor/cccDNA Inhibitor - Roche
Lu Gao
Roche, China

 1:55 PM

Elimination of Residual HBV Replication and Prevention of cccDNA Generation with the Combination of NrtI and Core Inhibitor
Richard Colonno
Assemby Biosciences

 2:05 PMsIRNA based therapy for Chronic Hepatitis B Treatment
Michael Biermer
Janssen
 2:15 PM

NAP's latest update in HBV and HDV
Andrew Vaillant
Replicor

 2:25 PM

MyrB + IFN effect on HBV & HDV
Stefan Urban
Heidelberg University Hospital

 2:35 PM

HDV Trials
Robert Gish
Robert G. Gish Consultants LLC

 2:45 PM Discussion
   
 3:30 PMCoffee Break
 Session 5: New Drug Combinations and Study Design
Chairs: Harry Janssen & Fabien Zoulim
 3:45 PMFDA Guidance on New Combinations
Poonam Mishra
US Food and Drug Administration, United States
 4:00 PM

Hypothesized Synergies in new cobmination treatment beyond nucs
Jordan Feld
Toronto Center for Liver Disease

 4:15 PM

Study Design with New Combinations
Marion Peters
University of California, San Francisco

 4:30 PMDiscussion
 5:15 PMClosure of workshop
Harry Janssen
   
 6:30 PMNetworking Dinner